Up until recently, the stock has been a chronic underperformer.
Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.
Is 2026 the year Pfizer (NYSE: PFE) finally turns things around? The company has been struggling over the past few years due to poor financial results and looming patent cliffs. However, it has also ...
Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. 10 stocks we like better than Pfizer › Pfizer ...
Hosted on MSN
Pfizer targets monthly obesity shot. Why Lilly could still have the weight-loss heavyweight.
PfizerPFE stock toppled Tuesday after the S&P health giant reaffirmed its modest outlook for 2026 despite easily beating Wall Street's fourth-quarter expectations. The company also provided an update ...
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...
Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results